Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion
Status: Enrolling
Updated:  12/31/1969
START (South Texas Accelerated Research Therapeutics)
1780
mi
from 98109
San Antonio, TX
Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion
Status: Enrolling
Updated: 12/31/1969
START (South Texas Accelerated Research Therapeutics)
1780
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
2
mi
from 98109
Seattle, WA
Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion
Status: Enrolling
Updated:  12/31/1969
Istituto Clinico Humanitas
mi
from 98109
Milan,
Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion
Status: Enrolling
Updated: 12/31/1969
Istituto Clinico Humanitas
mi
from 98109
Milan,
Click here to add this to my saved trials
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
2373
mi
from 98109
Philadelphia, PA
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1220
mi
from 98109
Tucson, AZ
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1220
mi
from 98109
Tucson, AZ
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
984
mi
from 98109
Orange, CA
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
984
mi
from 98109
Orange, CA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2450
mi
from 98109
Gainesville, FL
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2450
mi
from 98109
Gainesville, FL
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1504
mi
from 98109
Westwood, KA
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1504
mi
from 98109
Westwood, KA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2099
mi
from 98109
New Orleans, LA
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2099
mi
from 98109
New Orleans, LA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2481
mi
from 98109
Scarborough, ME
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2481
mi
from 98109
Scarborough, ME
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2485
mi
from 98109
Boston, MA
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1933
mi
from 98109
Detroit, MI
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1933
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1393
mi
from 98109
Minneapolis, MN
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1393
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2394
mi
from 98109
Hackensack, NJ
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2394
mi
from 98109
Hackensack, NJ
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2400
mi
from 98109
New York, NY
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2373
mi
from 98109
Philadelphia, PA
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2424
mi
from 98109
Charleston, SC
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2424
mi
from 98109
Charleston, SC
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1937
mi
from 98109
Galveston, TX
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1937
mi
from 98109
Galveston, TX
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1890
mi
from 98109
Houston, TX
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Research Site
6918
mi
from 98109
Ciudad Autónoma de Buenos Aires,
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Research Site
6918
mi
from 98109
Ciudad Autónoma de Buenos Aires,
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2322
mi
from 98109
Washington,
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Center of Wake Forest University
2279
mi
from 98109
Winston-Salem, NC
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Center of Wake Forest University
2279
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials
Clinical and Histopathologic Characteristics of BAP1 Mutations
Clinical and Histopathologic Characteristics of BAP1 Mutations
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
2402
mi
from 98109
New York, NY
Clinical and Histopathologic Characteristics of BAP1 Mutations
Clinical and Histopathologic Characteristics of BAP1 Mutations
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Clinical and Histopathologic Characteristics of BAP1 Mutations
Clinical and Histopathologic Characteristics of BAP1 Mutations
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Westchester
2404
mi
from 98109
Harrison, NY
Clinical and Histopathologic Characteristics of BAP1 Mutations
Clinical and Histopathologic Characteristics of BAP1 Mutations
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Westchester
2404
mi
from 98109
Harrison, NY
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
984
mi
from 98109
Orange, CA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
984
mi
from 98109
Orange, CA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1026
mi
from 98109
Aurora, CO
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1026
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2450
mi
from 98109
Gainesville, FL
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2450
mi
from 98109
Gainesville, FL
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2527
mi
from 98109
Tampa, FL
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2527
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1939
mi
from 98109
Louisville, KY
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1939
mi
from 98109
Louisville, KY
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2454
mi
from 98109
Worcester, MA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2454
mi
from 98109
Worcester, MA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1393
mi
from 98109
Minneapolis, MN
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1393
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2400
mi
from 98109
New York, NY
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2400
mi
from 98109
New York, NY
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2161
mi
from 98109
Rochester, NY
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2132
mi
from 98109
Pittsburgh, PA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2132
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2132
mi
from 98109
Pittsburgh, PA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2132
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2348
mi
from 98109
Richmond, VA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2348
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
6892
mi
from 98109
Pilar,
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
6892
mi
from 98109
Pilar,
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1720
mi
from 98109
Saint Louis, MO
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1720
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2322
mi
from 98109
Washington,
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Phase II Trial of Sorafenib in Combination With Modified FOLFOX in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Phase II Trial of Sorafenib in Combination With Modified FOLFOX in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Phase II Trial of Sorafenib in Combination With Modified FOLFOX in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Phase II Trial of Sorafenib in Combination With Modified FOLFOX in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials